Pharmaceuticals
-
Bausch + Lomb IPO: A Good Investment?
Bausch + Lomb is about to go public with an IPO, so we're taking a look at the stock to see if there's a clear case for investing.
-
Algernon Pharma IPO: What You Need to Know
Algernon Pharma (CSE: AGN, FRANKFURT: AGWO, OTCQB: AGNPF) plans to list on the NASDAQ Capital Market in an IPO.
-
Is Rocket Pharmaceuticals Stock (RCKT) One to Watch in 2022?
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) hopes to use gene therapy to cure pediatric diseases. RCKT stock has been rising this month. Is it a buy?
-
SRRA Shares Higher: Sierra Oncology Cancer Drug Shines in Testing
Sierra Oncology (NASDAQ: SRRA) shares leapt by more than 25% on Wednesday after a breakthrough in the firm's quest to commercialize a blood cancer...
-
MRNA, PFE, BNTX, FSR, NVAX: Which Stocks are Trending Today 29 Nov?
A small recovery is expected on Monday morning after markets took a beating on Black Friday, with pharma continuing to rise and some travel stocks...
-
Is Pfizer Stock a Buy as COVID Pills Gear Up for Approval?
Pfizer's COVID-19 pill, vaccine and CFO resignation are making headlines this week. Does the news help boost its investment thesis?
-
The HighBrid Lab blends complementary therapies amid rising investor interest
Creso Pharma is joining forces with long-established psychedelics business Red Light Holland Corp.
-
Why Creso Pharma is Set to Be First-Mover in New Corner of Projected $16 Trillion Market
Creso Pharma's revolutionary approach to treating the $16 trillion mental health problem.
-
This firm is taking a diversified approach to two novel sectors helping millions worldwide...
Creso Pharma are entering a brand-new booming market as it rides the second green wave.
-
Biotech stock Cardiol Therapeutics makes progress with clinical trial
Cardiol Therapeutics advances CardiolRx trial with its first Covid-19 positive patient. The CBD formulation may hold the key to reducing CVD...
-
Agreement to acquire established Canadian psychedelics company Halucenex Life Sciences Inc.
Creso Pharma has signed an agreement to acquire Halucenex Life Sciences, an established psychedelics company focused on developing treatments...
-
This Company Has Developed a Range of Market-Leading Complementary Feed Products Specifically Formulated For Pets...
-
Pharma’s $7.2 Billion CBD Acquisition Could Trigger New Biotech Boom
-
How Cardiol Therapeutics Could Help Save the Most Vulnerable from Dying of COVID-19
-
This Company Is Maximizing its Growth in an Emerging Sector With a Three-Pillar Strategy
-
Open Orphan rises as Venn wins major contract renewal with biopharma play
Sign up for VTM Updates
Top Picks for Q2 2022
View MoreCrypto Corner
Learn your NFTs from your BTCs